Xact Kapitalforvaltning AB raised its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 14.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,551 shares of the health services provider’s stock after purchasing an additional 700 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Amedisys were worth $650,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC bought a new position in shares of Amedisys during the 2nd quarter worth $2,471,000. Advisors Asset Management Inc. bought a new position in shares of Amedisys during the 2nd quarter worth $1,460,000. United Services Automobile Association grew its position in shares of Amedisys by 22.2% during the 2nd quarter. United Services Automobile Association now owns 5,182 shares of the health services provider’s stock worth $443,000 after buying an additional 942 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Amedisys by 112.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 32,087 shares of the health services provider’s stock worth $4,010,000 after purchasing an additional 16,987 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in shares of Amedisys during the 3rd quarter worth $5,276,000. 96.45% of the stock is owned by hedge funds and other institutional investors.
Amedisys stock traded down $0.73 during midday trading on Tuesday, reaching $131.33. The company’s stock had a trading volume of 5,143 shares, compared to its average volume of 315,161. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.06 and a current ratio of 1.06. Amedisys Inc has a 52-week low of $54.06 and a 52-week high of $140.91. The stock has a market cap of $4.21 billion, a PE ratio of 59.95, a price-to-earnings-growth ratio of 1.72 and a beta of 1.43.
A number of equities research analysts recently weighed in on AMED shares. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $140.00 price objective for the company in a research note on Wednesday, January 23rd. Benchmark upgraded Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a research note on Tuesday, October 30th. ValuEngine cut Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 11th. Finally, Barclays started coverage on Amedisys in a research note on Friday, December 14th. They set an “equal weight” rating and a $130.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $114.62.
TRADEMARK VIOLATION NOTICE: “Xact Kapitalforvaltning AB Raises Position in Amedisys Inc (AMED)” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4146256/xact-kapitalforvaltning-ab-raises-position-in-amedisys-inc-amed.html.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.